

# ZENEO® receives JANUS Prospective Award from the French Institute of Design

Crossject's **ZENEO®**, an unprecedented device for the needle-free injection of medical formulations, is the result of twenty years of R&D and protected by close to 400 patents.

The company is proud to announce that ZENEO® received the 2017 JANUS Prospective award from the French Institute of Design. This award recognizes the forward-looking vision of Crossject and the determination of its founder, Patrick Alexandre, to overcome the numerous challenges in the device's conception and particularly its ergonomics, a core aspect present from the start and developed in collaboration with patients and healthcare professionals.

Promoted by the French Ministry for the Economy and Finance, this JANUS award reinforces Crossject's ambition of becoming the world's leading pharmaceutical laboratory for self-administered emergency products.

## ZENEO®, a unique technology worldwide



**ZENEO® is a prefilled, single-use device capable of propelling a medical formulation through the skin in only 50 milliseconds.** Its injection parameters are entirely factory-set according to the viscosity, dosage and injection route (subcutaneous or intramuscular) of the drug formulation. For a needle-free auto-injector, this versatility is unmatched anywhere in the world.

The novel technology and revolutionary design of ZENEO® make it particularly well-suited for patients facing emergency situations, and resultantly, Crossject has chosen to focus its efforts on that segment. Today, the company's portfolio contains eight products in advanced stages of development, **seven of which are for urgent or life-threatening situations.**

## ZENEO®, an original concept developed for patients

Beyond ensuring compatibility with the requirements of American and European medical agencies, **the ergonomics of ZENEO® were carefully developed in partnership with not only Capital Innovation**, an industrial design and innovation agency, **but also patients themselves**, to make certain their independence with the device.

**Its compactness, weight, shape, prehension and ease-of-use were all subjected to in-depth studies.** For example, the quick opening mechanism of ZENEO® can be easily actioned by patients with hand mobility issues, and its visual cues provide a simple and intuitive guide for its use. Over years of development, ZENEO® has been precisely tailored to the needs of patients living with invalidating or life-threatening disorders.

**The original design of ZENEO® also favors compliance for regularly-administered treatments** by removing any fear of needles or risk of wounds and by guaranteeing that the entire dose is correctly administered. ZENEO® delivers its advantages in a simple, one-handed gesture with no contamination risks thanks to its single-use nature.




## An unprecedented multidisciplinary approach, an alliance of space, automotive and pharmaceutical technologies

**ZENEO® finds its origins in the combination and miniaturization of cutting-edge technologies used in the automobile and space sectors.**

On one end there is a siliconized, depyrogenated, pharmaceutical-quality glass tube (unique technique worldwide) that can support up to 1,200 bars of pressure, in contact with a polycarbonate nozzle with submillimeter conduits. On the other is a reaction-based gas generator with an actuator that includes an innovative unlocking and opening system.

The actuator activates the generator and the resulting gas propels the liquid formulation at a very high speed. The first phase propels the product through the skin and the second diffuses the medical substance at the desired depth.



### About the French Institute of Design's JANUS awards

**Since 1953, the JANUS jury has been convening in 10 yearly sessions to reward excellence in and the collaborative dimension of design.**



JANUS 2017  
DE LA PROSPECTIVE

The jury unites about 60 members representing such fields as architecture, design, industry, commerce and academia. This diversity enables a meeting of minds and a multiplication of perspectives for the range of considered projects.

Products honored with the JANUS label share not only originality and creativity but also pertinence for the «5 E's»: Economy, Ergonomics, Esthetics, Ethics, Emotion; the cornerstone values of the French Institute of Design.

### About Crossject

**ZENEO® is the manifestation of Crossject's expertise in the needle-free injection of therapeutic formulations, an expertise unmatched elsewhere on the globe. ZENEO® is the result of nearly 20 years of R&D and it has earned close to 400 patents.**

The company's portfolio currently contains **eight products in advanced stages of development, seven of which are for urgent or life-threatening situations.** Crossject aims to become the world leader in self-administered emergency treatments.

Crossject has been listed on the Euronext Growth market since February 2014. The company has completed three fund raising campaigns and furthermore received financing from the French Ministry of Defense and grants from Bpifrance as part of the Investissements d'Avenir program.

[www.crossject.com](http://www.crossject.com)

### Press contacts:

#### BUZZ & COMPAGNIE

**Mélanie Voisard**

06 12 52 53 15

[melanie.voisard@buzzetcompagnie.com](mailto:melanie.voisard@buzzetcompagnie.com)

**Audrey Lachat**

06 09 96 51 70

[audrey.lachat@buzzetcompagnie.com](mailto:audrey.lachat@buzzetcompagnie.com)